Why full FDA approval of the Pfizer vaccine wasn't the 'silver bullet' for vaccination rates


Even though health officials had hoped the opposite to be true, a federal government analysis suggests full FDA approval of Pfizer's COVID-19 vaccine had only a "modest and relatively short-lived" effect on vaccination rates, CNN reports. In other words, while there was a resulting uptick, full licensure was not the "silver bullet" to completely eliminate vaccine hesitancy.
"There weren't suddenly lines around the block," said Becca Siegel, a senior adviser to the U.S. Department of Health and Human Services. That's because for "truly undecided people, this is a complex decision. It's not one thing," Siegel explained.
Notably, fear (whether that's of getting sick or of missing out), social pressure from friends and families, employer mandates, and concerns regarding the Delta variant were more likely to bolster vaccination rates in hesitant individuals than full FDA approval, CNN notes, per polling from the Kaiser Family Foundation.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Still, licensure could play an otherwise long-term role in convincing Americans to roll up their sleeves. "We won't see the impact of approval on day one, hour one, but could see it over a long period of time," said Siegel. "This is a slow, steady march."
And as the U.S. inches toward the finish line, "I think we've come to recognize that mandates are what we've come to in order to really generate increases in vaccination," added John Browstein of Boston Children's Hospital. "Mandates are super important to cover the last mile for those who are on the fence." Read more at CNN.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Brigid Kennedy worked at The Week from 2021 to 2023 as a staff writer, junior editor and then story editor, with an interest in U.S. politics, the economy and the music industry.
-
Can Iran's government survive war with Israel?
Talking Points 'Regime change' may be on the agenda
-
Hot for summer with these 10 tours from some of music's best artists
The Week Recommends Get ready for sing-along sunshine
-
Why are lobbyists trying to kill Trump's 'revenge tax'?
Today's Big Question Analysts say it would deter foreign investment
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr.: A new plan for sabotaging vaccines
Feature The Health Secretary announced changes to vaccine testing and asks Americans to 'do your own research'
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia